Alvocidib clinical trials
Also written HMR 1275, L-868275 and flavopiridol.
- studies test it
- 50
- open now
- 0
- in phase 3
- 0
- first study started
- 1997
How each study uses alvocidib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
50 studies that test it; most in 2004 (7)
| Year | Studies |
|---|---|
| 1997 | 2 |
| 1998 | 1 |
| 1999 | 1 |
| 2000 | 3 |
| 2001 | 4 |
| 2002 | 5 |
| 2003 | 4 |
| 2004 | 7 |
| 2005 | 2 |
| 2006 | 7 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 45
National Cancer Institute (NCI) (39) · Sumitomo Pharma America, Inc. (3) · NCIC Clinical Trials Group (3) · AbbVie (1) · Gynecologic Oncology Group (1) · SWOG Cancer Research Network (1) · Sanofi (1) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Cytarabine (5) · Mitoxantrone (5) · Irinotecan (4) · Fluorouracil (3) · Gemcitabine (3) · Venetoclax (2) · Oxaliplatin (2) · Cisplatin (2)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses alvocidib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 50
- Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).CompletedPhase 1Sumitomo Pharma America, Inc.NCT03298984Written as AlvocidibHow we know
- Alvocidib Biomarker-driven Phase 2 AML StudyTerminatedPhase 2Sumitomo Pharma America, Inc.NCT02520011Written as AlvocidibHow we know
- Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination TherapyTerminatedPhase 2Sumitomo Pharma America, Inc.NCT03969420Written as Alvocidib (flavopiridol) and cytarabine (Ara-C)How we know
- A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid LeukemiaCompletedPhase 1AbbVieNCT03441555Written as AlvocidibHow we know
- Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AMLWithdrawnPhase 1/2M.D. Anderson Cancer CenterNCT04493099Written as Alvocidib HydrochlorideHow we know
- Flavopiridol in Treating Patients With Previously Untreated or Relapsed Mantle Cell LymphomaCompletedPhase 2NCIC Clinical Trials GroupNCT00005074Written as alvocidibHow we know
- Flavopiridol in Treating Patients With Metastatic Malignant MelanomaCompletedPhase 2NCIC Clinical Trials GroupNCT00005971Written as alvocidibHow we know
- Flavopiridol in Treating Patients With Recurrent, Locally Advanced, or Metastatic Soft Tissue SarcomaCompletedPhase 2NCIC Clinical Trials GroupNCT00005974Written as alvocidibHow we know
- Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or MediastinumTerminatedPhase 1National Cancer Institute (NCI)NCT00094978Written as Flavopiridol (alvocidib)How we know
- Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedPhase 2National Cancer Institute (NCI)NCT00795002Written as alvocidibHow we know
- Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell LymphomaCompletedPhase 1/2National Cancer Institute (NCI)NCT00445341Written as FlavopiridolHow we know
- Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedPhase 2National Cancer Institute (NCI)NCT01349972Written as alvocidibHow we know
- Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic LymphomaCompletedPhase 1/2National Cancer Institute (NCI)NCT00058240Written as alvocidibHow we know
- Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell TumorsCompletedPhase 2National Cancer Institute (NCI)NCT00957905Written as Alvocidib HydrochlorideHow we know
- Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic LeukemiaTerminatedPhase 2National Cancer Institute (NCI)NCT00098371Written as alvocidibHow we know
- Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaTerminatedPhase 1/2National Cancer Institute (NCI)NCT00112723Written as alvocidibHow we know
- Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedPhase 1National Cancer Institute (NCI)NCT01076556Written as Alvocidib HydrochlorideHow we know
- Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedPhase 2National Cancer Institute (NCI)NCT00407966Written as alvocidibHow we know
- Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedPhase 2National Cancer Institute (NCI)NCT00634244Written as alvocidibHow we know
- Flavopiridol in Treating Patients With Refractory CancerCompletedPhase 1National Cancer Institute (NCI)NCT00019344Written as alvocidibHow we know
See all 50 studies that test alvocidib →
Given beside what is tested · 3 — alvocidib is usual care or a partner of the new treatment
- A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid LeukemiaCompletedPhase 1Sumitomo Pharma Co., Ltd.NCT03563560Written as AlvocidibHow we know
- Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute LeukemiaCompletedPhase 1/2National Cancer Institute (NCI)NCT00016016Written as alvocidibHow we know
- Gemcitabine Plus Flavopiridol in Treating Patients With Advanced Solid TumorsCompletedPhase 1National Cancer Institute (NCI)NCT00007917Written as alvocidibHow we know
Codes
What other systems call alvocidib · ClinicalTrials.gg INT003677
- MeSH (NLM) C077990alvocidibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 45AD6X575GALVOCIDIBConfirmed FDA, NLM, Wikidata
- Wikidata Q4063441alvocidibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C74940AlvocidibOne source FDA
- DrugBank DB03496One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C077990 | alvocidib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 45AD6X575G | ALVOCIDIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q4063441 | alvocidib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C74940 | Alvocidib | One source FDA |
| DrugBank | DB03496 | — | One source Wikidata |
Also registered as alvocidib hydrochloride (UNII D48MS3A6N9).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.